Chris focuses his practice on privacy, data protection and cybersecurity. He advises companies across a range of industries on US and international regulatory compliance, risk management, information security governance, government investigations, and incident preparedness and response. Chris also has experience advising clients on privacy and data security issues in complex commercial agreements and corporate transactions.
Capstan Therapeutics Announces up to $2.1 Billion Acquisition by AbbVie
June 30, 2025
Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie.
Cooley advised Decagon, an innovator in conversational artificial intelligence agents for customer experience, on its $131 million Series C financing round, pushing its total funding to $231 million.
Cooley advised Decagon, an innovator in conversational artificial intelligence agents for customer experience, on its $131 million Series C financing round, pushing its total funding to $231 million.
Cooley advised Logik.ai, an industry leader offering a modern, artificial intelligence (AI)-powered, composable configure, price and quote solution, on its acquisition by ServiceNow (NYSE: NOW), the AI platform for business transformation.
Cooley advised Chemistry, an early-stage venture firm that leads investments in standout software companies at the Seed and Series A stages, on its $350 million debut fund, Chemistry Fund 1.
